Skip to main content
Top
Published in: Hormones 4/2021

01-12-2021 | Thyroid Cancer | Original Article

Improving the prediction of persistent and recurrent differentiated thyroid cancer using the American Thyroid Association 2015 risk stratification system

Authors: Georgios K. Markantes, Meropi Karakioulaki, Stavroula Papanikolopoulou, Anastasia Theodoropoulou, Kostas B. Markou, Apostolos G. Vagenakis, Trifon Spyridonidis, Dimitrios G. Goulis, Marina A. Michalaki

Published in: Hormones | Issue 4/2021

Login to get access

Abstract

Purpose

The 2015 American Thyroid Association risk stratification system (ATA RSS) is used in patients with differentiated thyroid carcinoma (DTC) to assess their risk of persistent/recurrent disease. Our aims were to validate the 2015 ATA RSS in a registry of DTC patients and to examine whether the addition of factors not included in it, such as pre-radioactive iodine therapy stimulated thyroglobulin (pre-RAI sTg), gender, and age could increase its predictive ability.

Methods

We studied 403 patients with DTC, treated at a tertiary center from 1990 to 2018 and subjected to total thyroidectomy. All patients had received RAI therapy, except those with low-risk papillary microcarcinoma.

Results

Of our patients, 81.9% were women and 91.1% had papillary thyroid carcinoma. After a median follow-up of 5.0 years, 53 cases of persistent and 21 cases of recurrent disease were recorded. The proportion of variance explained (PVE) regarding the outcome (presence or absence of recurrent/persistent disease) using the 2015 ATA RSS alone was 18.3% (persistence) and 16.9% (recurrence), increasing to 74.4% and 52.0%, respectively, when pre-RAI sTg was added to the logistic regression model. Gender and age were not associated with the disease outcome. In ROC analysis, pre-RAI sTg had a high predictive value for persistent (AUC 0.983, 95% CI 0.962–1.000) and recurrent disease (AUC 0.856, 95% CI 0.715–0.997). The optimal cut-offs and sensitivity, specificity, and positive and negative predictive value for pre-RAI sTg were the following: for persistence 12.75 ng/ml, 100%, 90.5%, 64%, and 100%, and for recurrence 8.05 ng/ml, 77.8%, 85.5%, 36.8%, and 97%.

Conclusions

The 2015 ATA RSS displayed moderate performance in predicting recurrent/persistent disease in patients with DTC, which improved with the inclusion of pre-RAI sTg values; pre-RAI sTg was an independent predictor of the disease outcome, with high negative prognostic value.
Literature
1.
go back to reference Tran B, Roshan D, Abraham E, Wang L, Garibotto N, Wykes J et al (2018) An analysis of the American Joint Committee on Cancer 8th edition T staging system for papillary thyroid carcinoma. J Clin Endocrinol Metab 103:2199–2206CrossRef Tran B, Roshan D, Abraham E, Wang L, Garibotto N, Wykes J et al (2018) An analysis of the American Joint Committee on Cancer 8th edition T staging system for papillary thyroid carcinoma. J Clin Endocrinol Metab 103:2199–2206CrossRef
2.
go back to reference Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L (2016) Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med 375:614–617CrossRef Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L (2016) Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med 375:614–617CrossRef
3.
go back to reference Li M, Brito JP, Vaccarella S (2020) Long-term declines of thyroid cancer mortality: an international age-period-cohort analysis. Thyroid 30:838–846CrossRef Li M, Brito JP, Vaccarella S (2020) Long-term declines of thyroid cancer mortality: an international age-period-cohort analysis. Thyroid 30:838–846CrossRef
4.
go back to reference Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167CrossRef Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167CrossRef
5.
go back to reference Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133CrossRef Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133CrossRef
6.
go back to reference Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G et al (2011) Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 165:441–446CrossRef Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G et al (2011) Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 165:441–446CrossRef
7.
go back to reference Nilubol N, Zhang L, Kebebew E (2013) Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin. Thyroid 23:695–702CrossRef Nilubol N, Zhang L, Kebebew E (2013) Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin. Thyroid 23:695–702CrossRef
8.
go back to reference Trimboli P, Piccardo A, Signore A, Valabrega S, Barnabei A, Santolamazza G et al (2020) Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American Thyroid Association Stratification System. Thyroid 30:713–719CrossRef Trimboli P, Piccardo A, Signore A, Valabrega S, Barnabei A, Santolamazza G et al (2020) Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American Thyroid Association Stratification System. Thyroid 30:713–719CrossRef
9.
go back to reference Michalaki M, Bountouris P, Roupas ND, Theodoropoulou A, Agalianou N, Alexandrides T et al (2016) Low-risk papillary thyroid carcinoma patients who underwent near-total thyroidectomy without prophylactic central compartment lymph node dissection and were ablated with low-dose 50mCi RAI had excellent 10-year prognosis. Hormones (Athens) 15:511–517 Michalaki M, Bountouris P, Roupas ND, Theodoropoulou A, Agalianou N, Alexandrides T et al (2016) Low-risk papillary thyroid carcinoma patients who underwent near-total thyroidectomy without prophylactic central compartment lymph node dissection and were ablated with low-dose 50mCi RAI had excellent 10-year prognosis. Hormones (Athens) 15:511–517
10.
go back to reference Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M et al (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341–1349CrossRef Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M et al (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341–1349CrossRef
11.
go back to reference Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R et al (2012) Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf) 77:132–138CrossRef Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R et al (2012) Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf) 77:132–138CrossRef
12.
go back to reference Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM (2013) Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. Thyroid 23:1401–1407CrossRef Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM (2013) Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. Thyroid 23:1401–1407CrossRef
13.
go back to reference Yu XM, Wan Y, Sippel RS, Chen H (2011) Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 254:653–660CrossRef Yu XM, Wan Y, Sippel RS, Chen H (2011) Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 254:653–660CrossRef
14.
go back to reference Yao R, Chiu CG, Strugnell SS, Gill S, Wiseman SM (2011) Gender differences in thyroid cancer: a critical review. Expert Rev Endocrinol Metab 6:215–243CrossRef Yao R, Chiu CG, Strugnell SS, Gill S, Wiseman SM (2011) Gender differences in thyroid cancer: a critical review. Expert Rev Endocrinol Metab 6:215–243CrossRef
15.
go back to reference Zahedi A, Bondaz L, Rajaraman M, Leslie WD, Jefford C, Young JE et al (2020) Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation. Thyroid 30:871–877CrossRef Zahedi A, Bondaz L, Rajaraman M, Leslie WD, Jefford C, Young JE et al (2020) Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation. Thyroid 30:871–877CrossRef
16.
go back to reference Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC et al (2005) Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90:1440–1445CrossRef Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC et al (2005) Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90:1440–1445CrossRef
17.
go back to reference Piccardo A, Arecco F, Puntoni M, Foppiani L, Cabria M, Corvisieri S et al (2013) Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival. Clin Nucl Med 38:18–24CrossRef Piccardo A, Arecco F, Puntoni M, Foppiani L, Cabria M, Corvisieri S et al (2013) Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival. Clin Nucl Med 38:18–24CrossRef
18.
go back to reference Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J et al (2012) The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab 97:2754–2763CrossRef Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J et al (2012) The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab 97:2754–2763CrossRef
19.
go back to reference McDow AD, Shumway CM, Pitt SC, Schneider DF, Sippel RS, Long KL (2019) Utility of early postoperative unstimulated thyroglobulin in influencing decision making in patients with papillary thyroid carcinoma. Ann Surg Oncol 26:4002–4007CrossRef McDow AD, Shumway CM, Pitt SC, Schneider DF, Sippel RS, Long KL (2019) Utility of early postoperative unstimulated thyroglobulin in influencing decision making in patients with papillary thyroid carcinoma. Ann Surg Oncol 26:4002–4007CrossRef
20.
go back to reference Tamilia M, Al-Kahtani N, Rochon L, Hier MP, Payne RJ, Holcroft CA et al (2011) Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma. Nucl Med Commun 32:212–220CrossRef Tamilia M, Al-Kahtani N, Rochon L, Hier MP, Payne RJ, Holcroft CA et al (2011) Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma. Nucl Med Commun 32:212–220CrossRef
21.
go back to reference Papaleontiou M, Review of: McDow AD, Shumway CM, Pitt SC, Schneider DF, Sippel RS, Long KL (2019) Utility of early postoperative unstimulated thyroglobulin in influencing decision making in patients with papillary thyroid carcinoma. Ann Surg Oncol. Clin Thyroidol 31:482–485 Papaleontiou M, Review of: McDow AD, Shumway CM, Pitt SC, Schneider DF, Sippel RS, Long KL (2019) Utility of early postoperative unstimulated thyroglobulin in influencing decision making in patients with papillary thyroid carcinoma. Ann Surg Oncol. Clin Thyroidol 31:482–485
22.
go back to reference Liu L, Zhang X, Tian T, Huang R, Liu B (2020) Prognostic value of pre-ablation stimulated thyroglobulin in children and adolescents with differentiated thyroid cancer. Thyroid 30:1017–1024CrossRef Liu L, Zhang X, Tian T, Huang R, Liu B (2020) Prognostic value of pre-ablation stimulated thyroglobulin in children and adolescents with differentiated thyroid cancer. Thyroid 30:1017–1024CrossRef
24.
go back to reference Salvatori M, Raffaelli M, Castaldi P, Treglia G, Rufini V, Perotti G et al (2007) Evaluation of the surgical completeness after total thyroidectomy for differentiated thyroid carcinoma. Eur J Surg Oncol 33:648–654CrossRef Salvatori M, Raffaelli M, Castaldi P, Treglia G, Rufini V, Perotti G et al (2007) Evaluation of the surgical completeness after total thyroidectomy for differentiated thyroid carcinoma. Eur J Surg Oncol 33:648–654CrossRef
25.
go back to reference Tae K, Song CM, Ji YB, Kim KR, Kim JY, Choi YY (2014) Comparison of surgical completeness between robotic total thyroidectomy versus open thyroidectomy. Laryngoscope 124:1042–1047CrossRef Tae K, Song CM, Ji YB, Kim KR, Kim JY, Choi YY (2014) Comparison of surgical completeness between robotic total thyroidectomy versus open thyroidectomy. Laryngoscope 124:1042–1047CrossRef
26.
go back to reference Ahn JH, Yi JW (2020) Transoral endoscopic thyroidectomy for thyroid carcinoma: outcomes and surgical completeness in 150 single-surgeon cases. Surg Endosc 34:861–867CrossRef Ahn JH, Yi JW (2020) Transoral endoscopic thyroidectomy for thyroid carcinoma: outcomes and surgical completeness in 150 single-surgeon cases. Surg Endosc 34:861–867CrossRef
27.
go back to reference Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH et al (2019) Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 29:461–470CrossRef Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH et al (2019) Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid 29:461–470CrossRef
28.
go back to reference Luster M, Aktolun C, Amendoeira I, Barczyński M, Bible KC, Duntas LH et al (2019) European perspective on 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: Proceedings of an Interactive International Symposium. Thyroid 29:7–26CrossRef Luster M, Aktolun C, Amendoeira I, Barczyński M, Bible KC, Duntas LH et al (2019) European perspective on 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: Proceedings of an Interactive International Symposium. Thyroid 29:7–26CrossRef
29.
go back to reference Haddad R, Bischoff L, Bernet V, Blomain E, Busaidy NL, Dickson P et al (2020) NCCN clinical practice guidelines in Oncology (NCCN Guidelines®), Thyroid Carcinoma, Version 2.2020 Haddad R, Bischoff L, Bernet V, Blomain E, Busaidy NL, Dickson P et al (2020) NCCN clinical practice guidelines in Oncology (NCCN Guidelines®), Thyroid Carcinoma, Version 2.2020
Metadata
Title
Improving the prediction of persistent and recurrent differentiated thyroid cancer using the American Thyroid Association 2015 risk stratification system
Authors
Georgios K. Markantes
Meropi Karakioulaki
Stavroula Papanikolopoulou
Anastasia Theodoropoulou
Kostas B. Markou
Apostolos G. Vagenakis
Trifon Spyridonidis
Dimitrios G. Goulis
Marina A. Michalaki
Publication date
01-12-2021
Publisher
Springer International Publishing
Published in
Hormones / Issue 4/2021
Print ISSN: 1109-3099
Electronic ISSN: 2520-8721
DOI
https://doi.org/10.1007/s42000-021-00313-2

Other articles of this Issue 4/2021

Hormones 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine